NSC 364432
Alternative Names: 2-chloroethyl-3-sarcosinamide-1-nitrosourea; SarCNU; SarNULatest Information Update: 06 May 2003
At a glance
- Originator National Cancer Institute (USA)
- Developer National Cancer Institute (Canada)
- Class Antineoplastics; Small molecules
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Glioma